Pertuzumab
- Generic Name
- Pertuzumab
- Brand Names
- Perjeta, Perjeta-Herceptin, Phesgo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 380610-27-5
- Unique Ingredient Identifier
- K16AIQ8CTM
- Background
Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). It consists of two heavy chains and two lights chains that have 448 and 214 residues respectively. It was first approved by the FDA in 2012 for use with docetaxel and another HER2-targeted monoclonal antibody, trastuzumab, in the treatment of metastatic HER2-positive breast cancer. Its indicated conditions have since expanded to include use as both a neoadjuvant therapy and an adjuvant therapy in the treatment of HER2-positive breast cancers at high risk of recurrence.
- Indication
Pertuzumab is indicated for intravenous administration in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. It is also indicated in combination with trastuzumab and other chemotherapies for the neoadjuvant treatment of HER2-positive locally advanced, inflammatory, or early-stage breast cancer as part of a complete treatment regimen and as adjuvant treatment in patients with HER2-positive early-stage breast cancer at high risk of recurrence.
Pertuzumab is also indicated for subcutaneous injection - in combination with trastuzumab and hyaluronidase - in the treatment of HER2-positive breast cancers in adults.
- Associated Conditions
- Inflammatory Breast Cancer (IBC), Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer, Stage I Breast Cancer
- Associated Therapies
- -
Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy
- Conditions
- Interventions
- First Posted Date
- 2014-09-30
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 45
- Registration Number
- NCT02252887
- Locations
- 🇺🇸
Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸Hartford Healthcare Cancer Institute @ Hartford Hospital, Hartford, Connecticut, United States
🇺🇸Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-08-29
- Last Posted Date
- 2022-12-02
- Lead Sponsor
- US Oncology Research
- Target Recruit Count
- 33
- Registration Number
- NCT02229149
- Locations
- 🇺🇸
19 Sites, Multiple Locations, Texas, United States
Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2014-07-31
- Last Posted Date
- 2023-12-28
- Target Recruit Count
- 171
- Registration Number
- NCT02205047
- Locations
- 🇧🇪
University Hospital Gent, Gent, Vlaanderen, Belgium
🇵🇹Instituto Portugues De Oncologia - Centro Do Porto, Porto, Portugal
🇪🇪North Estonia Medical Centre, Tallinn, Estonia
Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-05-15
- Last Posted Date
- 2021-02-04
- Target Recruit Count
- 15
- Registration Number
- NCT02139358
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-05-07
- Last Posted Date
- 2021-09-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 401
- Registration Number
- NCT02132949
- Locations
- 🇵🇱
Wielkopolskie Centrum Onkologii; im. Marii Skłodowskiej-Curie, Poznan, Poland
🇵🇹Centro Clinico Champalimaud; Oncologia Medica, Lisboa, Portugal
🇺🇸Berkshire Medical Center, Pittsfield, Massachusetts, United States
A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-05-06
- Last Posted Date
- 2019-07-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 444
- Registration Number
- NCT02131064
- Locations
- 🇺🇸
Cancer Care Assoc Med Group, Los Angeles, California, United States
🇺🇸New England Cancer Specialists, Scarborough, Maine, United States
🇺🇸Hope A Women's Cancer Center, Asheville, North Carolina, United States
A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)
- Conditions
- Interventions
- First Posted Date
- 2014-04-29
- Last Posted Date
- 2017-07-13
- Lead Sponsor
- German Breast Group
- Target Recruit Count
- 961
- Registration Number
- NCT02125344
- Locations
- 🇩🇪
NTC, Heidelberg, Baden-Württemberg, Germany
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
- First Posted Date
- 2014-03-19
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 673
- Registration Number
- NCT02091141
- Locations
- 🇺🇸
University Of Chicago Medical Center; Section Of Hematology/Oncology, Chicago, Illinois, United States
🇺🇸MD Anderson, Houston, Texas, United States
🇺🇸University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel
- Conditions
- Interventions
- First Posted Date
- 2014-02-27
- Last Posted Date
- 2021-09-22
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 32
- Registration Number
- NCT02073487
- Locations
- 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
🇺🇸Houston Methodist Hospital Sugar Land, Sugar Land, Texas, United States
🇺🇸Houston Methodist Hospital Willowbrook, Houston, Texas, United States
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
- First Posted Date
- 2014-02-06
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 198
- Registration Number
- NCT02057133
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Highlands Oncology Group - Duplicate 2, Rogers, Arkansas, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.